key: cord-0929326-i6d4ibf0
authors: Li, Li; Li, Siqi; Pan, Yang; Qin, Ling; Yang, Siyuan; Tan, Dawei; Hu, Yaling; Knoll, Maria Deloria; Wang, Xiaoli; Wang, Linghang; Wang, Quanyi
title: An Immunocompetent Patient with High Neutralizing Antibody Titers Who Shed COVID-19 Virus for 169 days — China, 2020
date: 2021-08-06
journal: China CDC Wkly
DOI: 10.46234/ccdcw2021.163
sha: 9e31a9ee8a30cd01a86eb86400bbcde53aa37ed8
doc_id: 929326
cord_uid: i6d4ibf0

Few reports are available about prolonged shedding of coronavirus disease (COVID-19) virus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by immunocompetent patients. We report a case of an infected, immunocompetent person with 169 days of COVID-19 virus shedding during which time he had two brief periods when he tested negative for COVID-19 followed by again testing positive. We describe relevant clinical, immunological, and genomic features. We found that continuous and prolonged viral replication and infectivity existed in an immunocompetent COVID-19 patient, despite having high neutralizing antibody titers. INTRODUCTION Previous case reports have described immunocompromised patients shedding COVID-19 virus RNA for 105 days and 153 days, and to our knowledge, the longest reported duration of COVID-19 virus shedding in an immunocompetent COVID-19 patient was 61 days (1-3). In this report, we describe an immunocompetent COVID-19 case in Beijing with 169 days of viral shedding.

Previous case reports have described immunocompromised patients shedding COVID-19 virus RNA for 105 days and 153 days, and to our knowledge, the longest reported duration of COVID-19 virus shedding in an immunocompetent COVID-19 patient was 61 days (1-3). In this report, we describe an immunocompetent COVID-19 case in Beijing with 169 days of viral shedding.

A 64-year-old man with coronary atherosclerotic heart disease, hypertension, and type-2 diabetes, with a 40-year history of smoking and alcohol consumption, was confirmed as a COVID-19 case on February 12, 2020. He was identified in a family cluster of COVID-19 virus infection ( Figure 1A ), in which 4 of 7 family members were confirmed to be COVID-19 cases and whose COVID-19 virus viral sequences were highly homologous. Overall, 3 family members recovered and were discharged by March, but the subject of this case report, who had moderately severe COVID-19, was isolated at the hospital due to persistent COVID-19 virus positivity until August of 2020, with an exception of two 2-week periods when he tested negative (4) ( Figure 1A , Supplementary Table S1 available in http://weekly.chinacdc.cn/).

The patient had chills, fever (38.6 °C), sore throat, and loss of appetite from February 1 to his admission on February 12. Clinical examination revealed decreased white blood cell (WBC) and lymphocyte counts (Supplementary Table S2 available in http:// weekly.chinacdc.cn/). Chest computed tomography (CT) showed patchy ground-glass opacities in the upper and the lower lobes under the pleura of both lungs and in the middle lobe of the right lung (Supplementary Figure S2 available in http://weekly. chinacdc.cn/). Throughout his hospitalization, no abnormalities were observed in his liver or kidney function or in routine blood examinations (Supplementary Table S3 available in http://weekly. chinacdc.cn/). Supportive evidence that he was immunocompetent was that all absolute cluster of differentiation 4 (CD4) counts were above 350/μL, the CD4/cluster of differentiation 8 (CD8) ratio was above 1, and he was HIV negative; however his CD8 cell counts and natural killer (NK) cell counts were low at times (Supplementary Table S3 ).

The patient's neutralizing antibody titer was 1∶2,048 measured 13 days after illness onset; the titer peaked at 1∶8,192 on day 24 and subsequently declined, staying at 1∶384 for over 9 months (Figure 1B; Supplementary (days 13, 17, 24, 45, 48, 58, 178, 199, 213, and 299) . To our knowledge, the patient we describe has the longest duration of viral shedding (169 days) with intra-host variants (151 days). The intra-host mutation rate was comparable to that seen with inter-host variants (7-8). However, unlike previous studies, which describe shorter infection periods, the mutations identified in this case appeared across the entire genome rather than in select hotspots, such as S and ORF8 genes (1-2).

Although previous studies suggested that COVID-19 patients positive for COVID-19 virus RNA following a period of being negative have little or no infectiousness (9-10), our evidence suggests infectiousness may last up to 151 days after symptom onset. Although lack of laboratory facilities precluded virus isolation and culture, the observed accumulated mutations and positive sgRNA 3-4 months after infection suggests continuous, on-going viral replication and therefore potential for transmission (1). We believe that more attention to the infectiousness of patients testing positive after a period of testing negative is warranted.

The patient did not have severe clinical symptoms, indicating that prolonged viral shedding can occur in moderately ill cases (11-12). Because frequent nucleic acid testing is normally only done in people with COVID-19-like symptoms, we may be underdetecting occurrence of long-term virus shedding (4).

We anticipate additional follow-up of this individual. Although a single case report may have limited generalizability, our observation that he shed virus despite his neutralizing antibody titers being much higher than titers we have seen with other patients at our facility (13) 

All available data on white blood cell (WBC), lymphocyte, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL) from liver function tests; albumin (ALB), blood urea nitrogen (BUN) and creatinine level (Cr) from kidney function tests, and computerized tomography (CT) images were obtained from clinical charts and tests results.

Neutralizing Antibody Ten blood samples were collected. Antibodies were assessed with a modified cytopathogenic neutralization assay (NA) using live COVID-19 virus. The dynamics of neutralizing antibody levels at different time points were analyzed. We conducted neutralization assay (NA) to evaluate antibody level according to the Reed-Muench method on day 5. Serum samples were inactivated at 56 °C for 30 minutes and serially diluted with cell culture medium in 2-fold steps. Diluted sera were mixed with a virus suspension of 100 median tissue culture infective dose in 96-well plates at a ratio of 1∶1, followed by 2 hours of incubation at 36.5 °C in a 5% carbon dioxide (CO 2 ) incubator; 1-2 × 10 4 Vero cells were then added to the serum-virus mixture, and the plates were incubated for 5 days at 36.5 °C in a 5% CO 2 incubator. Cytopathic effects in each well were recorded by microscope; neutralizing titers were calculated by the dilution number yielding a 50% protective condition. A titer of ≥1∶4 indicated seropositivity. Viral Load Viral loads were obtained from 33 nasopharyngeal swabs and 20 sputum samples collected at different time points during the patient's hospitalization. All available Cycle threshold (Ct) values for determining viral load were abstracted from 7500 software v2.3 from the 2 hospitals (Thermo Fisher Scientific, Beijing, China).

In addition, sub-genomic RNA (sgRNA) was monitored to evaluate transcription of COVID-19 virus. Fifteen nasopharyngeal swabs and four sputum samples collected from Day 100 to Day 157 were analyzed.

Longitudinal nasopharyngeal swabs and sputum samples were collected after diagnosis and then sequenced by Next Generation Sequencing (NGS). A total of 14 viral genome sequences were obtained from serial samples, including 9 genomes from sputum samples and 3 genomes from nasopharyngeal swabs collected from the study case, and 2 from nasopharyngeal swabs collected from his 2 family members. Viral Genomic RNA and Subgenomic RNA Detection A series of nasopharyngeal swabs and/or sputum samples were collected after diagnosis. Viral RNA was extracted by automated nucleic acid purification (KingFishe Flex Purification System, Thermo, Waltham, MA, USA) and diluted in 90 μL RNase-free H 2 O. The viral genomic RNA (gRNA) was amplified by real-time RT-PCR assay using 5 μL input RNA and commercial kits (Bojie, Shanghai, China). The subgenomic RNA (sgRNA) was detected by real-time RT-PCR assay using 5 μL of RNA, TaqMan Fast Virus 1-Step Master Mix (Thermo), and sgRNA specific primer/probe sets. The results were determined according to the manufacturer's instruction. Negative and positive controls were applied to ensure the quality of the tests. Next Generation Sequencing Viral RNA was extracted from patient nasopharyngeal swabs and sputum samples using automated nucleic acid purification (KingFisher Flex Purification System). First strand cDNA synthesis was performed with the SuperScript IV First Strand Synthesis System (Invitrogen, MA, USA), using 8 μL input RNA and random hexamers. Then tiled-PCR amplicons were generated by 25-32 PCR cycles using ARTIC nCoV-2019 sequencing protocol v3 (https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3). The primers for Pool 1 and 2 were synthesized by Sangon (Shanghai, China). NGS libraries were prepared by Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA) and sequenced on MiniSeq using 2 × 150 paired-end sequencing kits (Illumina). Negative control samples were processed and sequenced in parallel for each sequencing run as contamination control.

Quality control and adaptor trimming was done CLC Genomics Workbench (v10.0, Qiagen, Germany). The clean reads were mapped to the reference COVID-19 virus genome (GenBank: MN908947.3) using Bowtie2 and SAMtools. Variant calling was performed using Genome Analysis Toolkit (GATK, version 4.0.10). Single nucleotide polymorphic variants were filtered for quality (QUAL) >200 and quality by depth (QD) >20 and indels were filtered for QUAL >500 and QD >20 using the filter tool in bcftools, v1.9. Phylogenetic analysis was conducted using MAFFT v7. A maximum likelihood tree was inferred by N-J model with bootstrap of 1000, including the patient COVID-19 virus genomes, the reference genome sequence (GenBank: MN908947.3) and 494 representative genomes randomly selected from NCBI virus dataset by regions of interest. The final figure was made using iTOl (https://itol.embl.de/). The viral genomes reported in this study have been deposited in GISAID (https://www.gisaid.org).

SUPPLEMENTARY TABLE S1. The timeline of the course of patient treatment from illness onset to 299 days after onset. 

SARS-CoV-2/Beijing/214/2020 (Day 117) SARS-CoV-2/Beijing/213/2020 (Day 114) SARS-CoV-2/Beijing/217/2020 (Day 136) SARS-CoV-2/Beijing/218/2020 (Day 151) SARS-CoV-2/Beijing/215/2020 (Day 119) SARS-CoV-2/Beijing/216/2020

Day 112) SARS-CoV-2/Beijing/212/2020 (Day 113) SARS-CoV-2/Beijing/211/2020

CT scans of the patient's upper and lower lung on Feb 13. (B) and (B'), CT scans of upper and lower lung on Feb 25. (C) and (C'), CT scans of upper and lower lungs on March 12, the second hospital admission. (D) and (D') CT scan of upper and lower lungs on April 14. (E) and (E') CT scans of upper and lower lung on